449 related articles for article (PubMed ID: 35709811)
81. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
[TBL] [Abstract][Full Text] [Related]
82. Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types.
Ryser M; Berlaimont V; Karkada N; Mihalyi A; Rappuoli R; van der Most R
Expert Rev Vaccines; 2019 Mar; 18(3):309-322. PubMed ID: 30739514
[TBL] [Abstract][Full Text] [Related]
83. Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.
Benard VB; Castle PE; Jenison SA; Hunt WC; Kim JJ; Cuzick J; Lee JH; Du R; Robertson M; Norville S; Wheeler CM;
JAMA Oncol; 2017 Jun; 3(6):833-837. PubMed ID: 27685805
[TBL] [Abstract][Full Text] [Related]
84. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.
Brotherton JM; Budd A; Rompotis C; Bartlett N; Malloy MJ; Andersen RL; Coulter KA; Couvee PW; Steel N; Ward GH; Saville M
Papillomavirus Res; 2019 Dec; 8():100177. PubMed ID: 31319173
[TBL] [Abstract][Full Text] [Related]
85. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.
Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA;
J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594
[TBL] [Abstract][Full Text] [Related]
86. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.
Rodríguez AC; Schiffman M; Herrero R; Hildesheim A; Bratti C; Sherman ME; Solomon D; Guillén D; Alfaro M; Morales J; Hutchinson M; Katki H; Cheung L; Wacholder S; Burk RD
J Natl Cancer Inst; 2010 Mar; 102(5):315-24. PubMed ID: 20157096
[TBL] [Abstract][Full Text] [Related]
87. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
Sakamoto M; Miyagi E; Sumi Y; Aisaka K; Kuno N; Nagano H; Asahara S; Han SR; Wakana A; Murata S; Sawata M; Tanaka Y
J Infect Chemother; 2019 Jul; 25(7):520-525. PubMed ID: 30879979
[TBL] [Abstract][Full Text] [Related]
88. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L; Hopkins L; Hutton B; Fergusson D
CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
[TBL] [Abstract][Full Text] [Related]
89. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.
Kitchener HC; Almonte M; Thomson C; Wheeler P; Sargent A; Stoykova B; Gilham C; Baysson H; Roberts C; Dowie R; Desai M; Mather J; Bailey A; Turner A; Moss S; Peto J
Lancet Oncol; 2009 Jul; 10(7):672-82. PubMed ID: 19540162
[TBL] [Abstract][Full Text] [Related]
90. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
Herweijer E; Sundström K; Ploner A; Uhnoo I; Sparén P; Arnheim-Dahlström L
Int J Cancer; 2016 Jun; 138(12):2867-74. PubMed ID: 26856527
[TBL] [Abstract][Full Text] [Related]
91. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.
Lang Kuhs KA; Gonzalez P; Rodriguez AC; van Doorn LJ; Schiffman M; Struijk L; Chen S; Quint W; Lowy DR; Porras C; DelVecchio C; Jimenez S; Safaeian M; Schiller JT; Wacholder S; Herrero R; Hildesheim A; Kreimer AR;
J Infect Dis; 2014 Dec; 210(12):1890-9. PubMed ID: 24958910
[TBL] [Abstract][Full Text] [Related]
92. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
93. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
[TBL] [Abstract][Full Text] [Related]
94. Estimating human papillomavirus vaccine efficacy from a single-arm trial: proof-of-principle in the Costa Rica Vaccine Trial.
Befano B; Campos NG; Egemen D; Herrero R; Schiffman M; Porras C; Lowy DR; Rodriguez AC; Schiller JT; Ocampo R; Hildesheim A; Sampson JN; Das S; Kreimer AR; Cheung LC;
J Natl Cancer Inst; 2023 Jul; 115(7):788-795. PubMed ID: 37040086
[TBL] [Abstract][Full Text] [Related]
95. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
Sand FL; Kjaer SK; Frederiksen K; Dehlendorff C
Int J Cancer; 2020 Aug; 147(3):641-647. PubMed ID: 31648368
[TBL] [Abstract][Full Text] [Related]
96. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing.
Lehtinen M; Apter D; Dubin G; Kosunen E; Isaksson R; Korpivaara EL; Kyhä-Osterlund L; Lunnas T; Luostarinen T; Niemi L; Palmroth J; Petäjä T; Rekonen S; Salmivesi S; Siitari-Mattila M; Svartsjö S; Tuomivaara L; Vilkki M; Pukkala E; Paavonen J
Int J STD AIDS; 2006 Aug; 17(8):517-21. PubMed ID: 16925896
[TBL] [Abstract][Full Text] [Related]
97. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies.
Kreimer AR; Herrero R; Sampson JN; Porras C; Lowy DR; Schiller JT; Schiffman M; Rodriguez AC; Chanock S; Jimenez S; Schussler J; Gail MH; Safaeian M; Kemp TJ; Cortes B; Pinto LA; Hildesheim A; Gonzalez P;
Vaccine; 2018 Aug; 36(32 Pt A):4774-4782. PubMed ID: 29366703
[TBL] [Abstract][Full Text] [Related]
98. Identification of vaccine human papillomavirus genotypes in squamous intraepithelial lesions (CIN2-3).
González-Bosquet E; Esteva C; Muñoz-Almagro C; Ferrer P; Pérez M; Lailla JM
Gynecol Oncol; 2008 Oct; 111(1):9-12. PubMed ID: 18684497
[TBL] [Abstract][Full Text] [Related]
99. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.
Palmer T; Wallace L; Pollock KG; Cuschieri K; Robertson C; Kavanagh K; Cruickshank M
BMJ; 2019 Apr; 365():l1161. PubMed ID: 30944092
[TBL] [Abstract][Full Text] [Related]
100. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica.
Wang SS; Trunk M; Schiffman M; Herrero R; Sherman ME; Burk RD; Hildesheim A; Bratti MC; Wright T; Rodriguez AC; Chen S; Reichert A; von Knebel Doeberitz C; Ridder R; von Knebel Doeberitz M
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1355-60. PubMed ID: 15298958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
